The Role of IL-23 Inhibitors in Crohn’s Disease - PMC
Abstract Promoting a Th17 pathogenic response, the interleukin (IL)-23 pathway is crucial in the pathophysiology of inflammatory bowel disease (IBD). With a favorable safety profile, …
Differentiating IL-23 Inhibitors in Crohn's Disease - PubMed
Interleukin-23 (IL-23), a member of the IL-12 family of cytokines, plays a critical role in intestinal homeostasis and inflammation and is strongly implicated in the pathogenesis of inflammatory …
David Fudman, MD, on Overseeing All The New Therapies for Crohn's Disease
For example, we suggest considering selective anti-IL-23 agents as first-line therapy in Crohn's disease, depending on a patient's risk of disease-and treatment-related complications.
Use of Interleukin-23 Inhibitors for the Treatment of …
G&H Why did interleukin-23 inhibition become a treatment approach for inflammatory bowel disease? EL There are several reasons. One is that overexpression of interleukin (IL)-23 has …
Differentiating IL-23 Inhibitors in Crohn’s Disease | Drugs
Interleukin-23 (IL-23), a member of the IL-12 family of cytokines, plays a critical role in intestinal homeostasis and inflammation and is strongly implicated in the pathogenesis of inflammatory …
Efficacy and Safety of IL-12/23 and IL-23 Inhibitors for Crohn’s ...
Targeting interleukin-23 (IL-23) is an important therapeutic strategy for Crohn’s disease (CD). This systematic review and meta-analysis assessed the efficacy and safety of selective IL-23p19 …
The Role of IL-23 Inhibitors in Crohn’s Disease - MDPI
Promoting a Th17 pathogenic response, the interleukin (IL)-23 pathway is crucial in the pathophysiology of inflammatory bowel disease (IBD). With a favorable safety profile, …
Interleukin-23 Inhibitors for Inflammatory Bowel Disease: …
IL-23 inhibitors are safe and effective for treatment of moderate-to-severe inflammatory bowel disease and appear more effective than ustekinumab for Crohn's disease. The currently …
Personalised Medicine with IL-23 Blockers: Myth or Reality?
1. Introduction The advent of biologic therapy in the management of inflammatory bowel disease [IBD] has had a dramatic impact on treatment strategies, clinical outcomes, and morbidity in …
Treating Challenging Moderate to Severe Crohn Disease With IL-12/IL-23 ...
Agents targeting the IL-12, IL-23, and Th-17 pathways have shown efficacy and safety in patients with Crohn disease for whom previous TNF-inhibitor therapy has failed.